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Indications for medical compression
stockings in venous and lymphatic
disorders: An evidence-based
consensus statement
Eberhard Rabe1, Hugo Partsch2, Juerg Hafner3,
Christopher Lattimer4, Giovanni Mosti5, Martino Neumann6,
Tomasz Urbanek7, Monika Huebner8, Sylvain Gaillard9 and
Patrick Carpentier10
Abstract
Objective: Medical compression stockings are a standard, non-invasive treatment option for all venous and lymphatic
diseases. The aim of this consensus document is to provide up-to-date recommendations and evidence grading on the
indications for treatment, based on evidence accumulated during the past decade, under the auspices of the International
Compression Club.
Methods: A systematic literature review was conducted and, using PRISMA guidelines, 51 relevant publications were
selected for an evidence-based analysis of an initial 2407 unrefined results. Key search terms included: ‘acute’, CEAP’,
‘chronic’, ‘compression stockings’, ‘compression therapy’, ‘lymph’, ‘lymphatic disease’, ‘vein’ and ‘venous disease’.
Evidence extracted from the publications was graded initially by the panel members individually and then refined at
the consensus meeting.
Results: Based on the current evidence, 25 recommendations for chronic and acute venous disorders were made. Of
these, 24 recommendations were graded as: Grade 1A (n¼ 4), 1B (n¼ 13), 1C (n¼ 2), 2B (n¼ 4) and 2C (n¼ 1). The
panel members found moderately robust evidence for medical compression stockings in patients with venous symptoms
and prevention and treatment of venous oedema. Robust evidence was found for prevention and treatment of venous leg
ulcers. Recommendations for stocking-use after great saphenous vein interventions were limited to the first post-
interventional week. No randomised clinical trials are available that document a prophylactic effect of medical compres-
sion stockings on the progression of chronic venous disease (CVD). In acute deep vein thrombosis, immediate
compression is recommended to reduce pain and swelling. Despite conflicting results from a recent study to prevent
post-thrombotic syndrome, medical compression stockings are still recommended. In thromboprophylaxis, the role of
stockings in addition to anticoagulation is limited. For the maintenance phase of lymphoedema management, compres-
sion stockings are the most important intervention.
Conclusion: The beneficial value of applying compression stockings in the treatment of venous and lymphatic disease is
supported by this document, with 19/25 recommendations rated as Grade 1 evidence. For recommendations rated with
Grade 2 level of evidence, further studies are needed.
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Introduction
Compression therapy for the management of chronic
venous disease (CVD) and lymphoedema is a readily
available, non-invasive treatment option which is
widely practiced and extensively documented.1–3
However, there is a paucity of guidelines derived from
evidence reported in clinical trials for the management
of patients using compression therapy.4 Currently, the
majority of recommendations are based on expert opin-
ion rather than evidence. The purpose of this document
was to review the current evidence from the literature
supporting compression performed by medical com-
pression stockings (MCS) and use this to compile and
grade recommendations for use in clinical practice.
The International Compression Club (ICC) is an ad
hoc group of experts that includes clinicians involved in
compression therapy, as well as technical specialists from
companies manufacturing compression devices for clin-
ical use. The ICC published a consensus statement in
2008 on the use of compression therapy in the manage-
ment of venous and lymphatic diseases.4 The aim of this
article is to provide an update of the 2008 consensus
statement in order to answer the clinical questions that
were outstanding. Importantly, the 2008 consensus state-
ment was based on the clinical manifestation (C) stages of
the Clinical-Etiology-Anatomy-Pathophysiology (CEAP)
classiﬁcation.5 However, this consensus statement is
based on the clinical goals of treatment, with recommen-
dations based on the primary outcome of compression
treatment focusing on MCS only. The recommendations
in this consensus document are not intended to establish
the superiority of MCS or compression pressures over
other compression devices or treatment modalities.
Methods
Consensus panel
The consensus group that contributed to this statement
comprised eight international experts experienced in
compression therapy, representing diﬀerent medical
disciplines (angiology, dermatology and vascular sur-
gery). They were selected by Eberhard Rabe (the pri-
mary author) who appointed a consensus meeting
Chair, Hugo Partsch, and the remaining members.
The responsibility of the Chairs, supported by a secre-
tary, Sylvain Gaillard, was to perform and reﬁne the
literature searches, to use their personal records and
knowledge, and to select/compose the initial recom-
mendations as a framework for discussion.
Study design
A systematic literature search was performed for art-
icles published between 1 January 2007 and 8 July 2015
using PubMed. Key search terms included ‘acute’,
‘CEAP’, ‘chronic’, ‘compression therapy’, ‘compression
stockings’, ‘lymph’, ‘lymphatic disease’, ‘vein’ and
‘venous disease’. The searches produced 2407 results
initially and, subsequently, a total of 1789 results,
after reﬁnement (Figure 1).
Studies were deemed eligible if they were randomised
controlled trials (RCTs) or observational studies
reporting on the use of MCS and published in the
English language. Published evidence on the eﬀective-
ness of MCS was reviewed and critically appraised by
the Chairs, who concentrated on RCTs that addressed
the use of compression for a large number of clinical
indications. In addition, the consensus group members
searched their personal collections of papers for rele-
vant medical literature. Reviews were not evaluated and
duplicate publications within the CEAP classes were
excluded. The results of this search strategy were fur-
ther reﬁned by the consensus meeting Chairs, who
manually selected a total of 109 potentially relevant
publications from the list, as well as from an additional
meta-analysis. After a decision to include only litera-
ture on compression stockings, a further review by the
consensus meeting Chairs identiﬁed 51 relevant publi-
cations, which were selected as the evidence base for
review and critical appraisal.
The evidence was graded according to the recom-
mendations of Guyatt et al.6 (Table 1). For this, rat-
ings of ‘high’, ‘moderate’ or ‘low’ were given to three
core components of the respective studies: study qual-
ity; risk of bias; and beneﬁt versus risk. An initial
grading of the evidence and preliminary recommenda-
tions was developed by the meeting Chairs. The task
of making the ﬁnal selection of papers was divided
amongst all the panel members, with reference to the
recommendations on grading. In September 2015, all
panel members met in Frankfurt to share their opin-
ions and reach a consensus on a set of recommenda-
tions and on their ﬁnal grading of evidence, using the
preliminary recommendations and initial grading. In
ﬁnalising their proposals, the panel used the 2008
ICC-consensus statement as a basis and concentrated
on new publications that were published since 1
January 2007.
Recommendations
Patients with chronic venous disorders and healthy
individuals
Improvement of venous symptoms, quality of life and
oedema. Venous symptoms, which include heaviness
and tension or increasing pain, volume and oedema
formation in the lower leg whilst standing or sitting,
during the course of the day or in warm environments,
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are common in the general population and are indica-
tions for treatment with MCS.
Earlier studies reported that venous symptoms, qual-
ity of life (QoL) and oedema formation, in patients with
lower clinical classes of chronic venous diseases (CVD)
(C1s–C3), can be signiﬁcantly improved by low-pressure
compression stockings, compared with placebo stock-
ings.7,8 Bla¨ttler et al.9 reported similar ﬁndings for the
use of leg compression stockings with an ankle pressure
15mmHg (Table 2). Blazek et al.10 reported that, for
individuals with professions that require them to stand
for prolonged periods, such as hairdressing, and who
experience venous symptoms (including leg pain, feel-
ings of swelling and heaviness), wearing leg compression
stockings (15–20mmHg) can alleviate these symptoms.
A prospective randomised study that compared
thigh-high compression stockings (20–30mmHg) with
sclerotherapy in patients with C1 CVD showed
that compression therapy provides signiﬁcant relief of
aching (p< 0.0001), pain (p¼ 0.002), leg cramps
(p¼ 0.003) and restlessness (p< 0.05), while sclerother-
apy provides superior broad-spectrum symptom relief.11
Furthermore, in two prospective randomised studies in
patients with mild, moderate or severe CVD, Couzan
et al.12,13 compared progressive compression stockings
(i.e. where pressure progressively increases from the
ankle to the calf, where the pressure is the highest)
with degressive compression stockings (pressure
decreases gradually from the ankle to the calf, where
the pressure is the lowest). Feelings of heaviness, pain
and other lower leg symptoms were signiﬁcantly alle-
viated in both groups, but better results were achieved
in the progressive compression stockings group.
Mosti et al.14 have demonstrated that compression
stockings exerting a pressure of approximately
30mmHg are nearly as eﬀective for reducing chronic
leg oedema as high-pressure bandages with an initial
pressure over 60mmHg. In another study, Mosti
et al.15 randomised 40 legs (28 patients) with chronic
venous oedema to either short-stretch bandages of ini-
tial median pressure 67mmHg (interquartile range
(IQR): 55.7–73.0) applied weekly for two weeks, fol-
lowed by an elastic stocking for two weeks (group A)
or an initial light stocking of median pressure
24.5mmHg (IQR: 21.2–26.5) for 1 week followed by
superimposing a second stocking for three weeks
(group B). They reported an initial improvement in leg
volume at one week that was independent of the pres-
sure applied, with the reduction maintained by super-
imposing a second stocking. In a randomised controlled
Figure 1. PRISMA flow diagram of relevant literature identified.
PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses; RCTs: randomised controlled trial.
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setting, Sell et al.16 compared the eﬀectiveness of com-
pression stockings with surgery in patients with uncom-
plicated varicose veins. At two years, treatment
eﬀectiveness (as measured by the venous clinical severity
score (VCSS) and the venous segmental disease score
(VSDS)), was demonstrated by both treatment modal-
ities, but was greater with surgery. Brizzio et al.17 com-
pared the eﬀect of multiple-layer short-stretch bandages
with compression stockings (15–25mmHg) on the rate
of healing, pain and QoL, in patients with venous leg
ulcer (VLU), and where local pressure over the ulcer was
increased by pads. In both groups, pain was reduced by
50%. Healing rates at 90 days were similar (36% and
48% for compression stockings and bandages, respect-
ively) and time to healing was identical. In an RCT
comparing the eﬀectiveness of a four-layer compression
bandage (CB) system and a Class 3 (30–35mmHg) com-
pression hosiery system on healing and QoL in patients
with VLUs, Finlayson et al.18 reported that, at 24 weeks,
there was no signiﬁcant diﬀerence between groups in
healing, QoL or pain measures, although a four-layer
system produced a more rapid response.
Long-distance travellers should beneﬁt from stockings
for the prevention of oedema, especially when combined
with mobilisation. An RCT conducted in Australia
demonstrated that low-ankle pressure graduated compres-
sion tights (GCTs) reduce ﬂight-induced ankle oedema
and subjectively rated travel symptoms of leg pain, dis-
comfort and swelling, and improve energy levels, ability to
concentrate, alertness and post-ﬂight sleep.19
For the majority of studies discussed, diﬀerent com-
pression pressure levels have been compared. It is
Table 1. Grading recommendations.6
Grade
Description of
recommendation Benefit vs. risk
Methodological quality of
supporting evidence Implications
1A Strong recommendation,
high-quality evidence
Benefits clearly outweigh
risk and burdens, or
vice versa
RCTs without important
limitations or over-
whelming evidence
from observational
studies
Strong recommendation,
can apply to most
patients in most cir-
cumstances without
reservation
1B Strong recommendation,
moderate-quality
evidence
Benefits clearly outweigh
risk and burdens, or
vice versa
RCTs with important
limitations (inconsist-
ent results, methodo-
logical flaws, indirect,
or imprecise) or
exceptionally strong
evidence from obser-
vational studies
Strong recommendation,
can apply to most
patients in most cir-
cumstances without
reservation
1C Strong recommendation,
low-quality or very
low-quality evidence
Benefits clearly outweigh
risk and burdens, or
vice versa
Observational studies or
case series
Strong recommendation
but may change when
higher-quality evidence
is available
2A Weak recommendation,
high-quality evidence
Benefits closely balanced
with risks and burden
RCTs without important
limitations or over-
whelming evidence
from observational
studies
Weak recommendation;
best action may differ
depending on circum-
stances or patients’ or
societal values
2B Weak recommendation,
moderate-quality
evidence
Benefits closely balanced
with risks and burden
RCTs with important
limitations (inconsist-
ent results, methodo-
logical flaws, indirect,
or imprecise) or
exceptionally strong
evidence from obser-
vational studies
Weak recommendation;
best action may differ
depending on circum-
stances or patients’ or
societal values
2C Weak recommendation,
low-quality or very
low-quality evidence
Uncertainty in the esti-
mates of benefits, risks
and burden; benefits,
risk and burden may be
closely balanced
Observational studies or
case series
Very weak recommenda-
tions; other alterna-
tives may be equally
reasonable
4 Phlebology 0(0)
important to highlight that even low-pressure MCS
(10–20mmHg) are able to reduce symptoms and
oedema. In consequence, the pressure level should be
adapted to the severity of the disease and limited to the
lowest pressure leading to symptom and oedema relief.
This will also improve patient compliance. Finally, we
conclude that all levels of compression improve venous
symptoms and oedema.
Recommendation 1: We recommend the use of MCS to
alleviate venous symptoms in patients with CVD
(GRADE 1B)
Recommendation 2: We recommend the use of MCS to
improve QoL and venous severity scores in patients
with CVD (GRADE 1B)
Recommendation 3: We recommend the use of MCS to
prevent leg swelling in patients with CVD and in
healthy individuals at risk of leg swelling (e.g. during
long ﬂights; occupational leg swelling) (GRADE 1B)
Recommendation 4: We recommend the use of MCS to
reduce leg swelling in patients with CVD and occupa-
tional leg swelling (GRADE 1B)
Improvement of skin changes caused by chronic venous
disease. The improvement of skin changes – including
eczema, induration and lipodermatosclerosis, caused by
chronic venous insuﬃciency (CVI) – by compression
therapy is regularly observed in routine clinical prac-
tice. However, there is a paucity of evidence from
RCTs. The recommendation to use MCS for the
improvement of skin changes in general is therefore
based on low-level evidence.
Recommendation 5: We suggest MCS for the improve-
ment of skin changes in patients with CVD (GRADE
1C)
Vandongen and Stacey20 reported that MCS reduced
the area of lipodermatosclerosis in patients with healed
venous ulceration. A total of 153 patients with recently
healed VLUs were randomised to either below-knee
graduated MCS or no stockings. In patients in the com-
pression group, the area of lipodermatosclerosis had
reduced signiﬁcantly, compared with the control
group, after six months (p¼ 0.01) and 12 months
(p¼ 0.04). Within two years of patients entering the
study, the area of lipodermatosclerosis was signiﬁcantly
larger in patients with ulcer recurrence than in those
who did not re-ulcerate (293 cm2 vs. 50 cm2).
Lipodermatosclerosis was determined both visually
and by palpating the leg. A line was drawn on the
skin and along the border of the lipodermatosclerosis,
traced onto polythene and the area measured using
planimetry.
Recommendation 6: We recommend MCS for the
improvement of lipodermatosclerosis in patients with
CVD (GRADE 1B)
Prevention of venous leg ulcer recurrence. Following VLU
healing, the ulcer recurrence rate depends on the
compensation of the venous insuﬃciency (either by
ablation of superﬁcial venous reﬂux, improvement
of deep venous pathology, where possible, or com-
pression treatment). In a Cochrane review that
included RCTs published until June 2000, Nelson
et al.21 investigated the eﬀect of compression on
VLU recurrence. No studies compared compression
versus no compression, while one RCT compared
‘high’ compression with ‘moderate’ compression
MCS and one study investigated diﬀerent medium-
pressure MCS. Compliance rates were signiﬁcantly
higher with medium compression vs. high compres-
sion MCS, and wearing MCS reduced the recurrence
rates signiﬁcantly. Nelson et al.22 compared the
eﬀectiveness of a ‘moderate’ (18–24mmHg) and a
‘high’ (25–35mmHg) compression MCS on venous
ulcer recurrence rates in patients with recently
healed VLU, with a ﬁve-year follow-up. There was
no signiﬁcant diﬀerence between the two groups but
the recurrence rate in the ‘high’ compression MCS
group was lower.
Clarke-Moloney et al.23 randomised 100 patients
with healed VLU to European Class 1 (18–
21mmHg) or Class 2 (23–32mmHg) MCS. After
12 months’ follow-up, there was no statistically sig-
niﬁcant diﬀerence in the ulcer recurrence rate
between MCS classes, although a greater number
of patients in the Class 1 group developed a recur-
rence and non-compliant patients were at signiﬁ-
cantly greater risk of recurrence (p 0.0001).
Patients who were compliant with MCS, regardless
of the compression level, had the lowest venous ulcer
recurrence rates. In a double-blind RCT conducted
within a nursing home setting, Kapp et al.24 com-
pared the eﬀectiveness of a 23–32mmHg and a
34–46mmHg compression stocking on venous ulcer
recurrence. The overall adherence to treatment was
low (44%). Non-adherence was signiﬁcantly higher in
the high-pressure MCS group (p¼ 0.003). Risk of
recurrence was greater in the ‘moderate’ compression
group than the ‘high’ compression group. Adherence
to treatment was found to signiﬁcantly predict ulcer
recurrence (p¼ 0.005).
The results of these studies show a trend of
lower rates of venous ulcer recurrence with higher-
compression MCS. However, compliance was lower in
the ‘high’ compression groups compared with the ‘mod-
erate’ compressions groups. In all studies, compliance
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with compression treatment signiﬁcantly reduced VLU
recurrence.
Recommendation 7: We recommend the use of MCS to
reduce recurrence of VLU (GRADE 1A)
Improvement of venous leg ulcer healing. VLUs are one of
the most important complications of CVI and they
have a great impact on patients’ QoL. CBs are widely
used in VLU treatment. A properly applied CB is
eﬀective but can be associated with problems of pres-
sure drop during the ﬁrst hours and a lack of standard-
isation, especially if the patient applies the
bandages themselves. Thus, CBs should be applied by
trained staﬀ.
In past decades, special ulcer MCS (‘ulcer kits’) have
been developed that comprise a two-layer stocking
system. The understocking keeps the ulcer-dressing in
place and can be used overnight, whilst an additional
higher-pressure overstocking is usually worn during
the day.
Following an earlier study by Partsch and
Horakova,25 who reported that MCS for venous
ulcers may be an eﬀective approach for ﬁt and coopera-
tive patients, Ju¨nger et al.26 reported that ulcer MCS
(ulcer kit), when compared with standard CB, were
superior in improving the healing rate of VLUs of a
moderate size. Time to healing was similar in both
groups. As discussed earlier, similar results were
reported by Brizzio et al. and also in comparison with
bandages.17
In a prospective, clinical pilot study, Dolibog et al.27
randomised 70 patients with unilateral VLUs to com-
pression therapy by intermittent pneumatic compres-
sion, MCS or short-stretch CB for 15 days. All
patients received saline-soaked gauze dressings along
with micronised puriﬁed ﬂavonoid fraction, diosmin,
hesperidin and oral Daﬂon 500mg once daily. Wound
size reduction and percentage of wounds healed were
signiﬁcantly higher in the groups receiving IPC or
stockings than in the groups using short-stretch
bandages.
Ashby et al.28 randomised 457 patients out of a total
of 3411 ulcer patients, presenting with VLUs of median
areas 4.1 cm2 and 3.7 cm2 to either two-layer ulcer MCS
(ulcer kit) or four-layer bandage treatment, respect-
ively. Median time to ulcer healing was 99 days (95%
conﬁdence interval (CI) 84–126) in the hosiery group
and 98 days (95% CI 85–112) in the bandage
group. The ulcer healing rate was similar in the
two groups (70.9% hosiery and 70.4% bandage).
Finlayson et al.18 reported results that were similar to
these, although in their study the four-layer system
showed a more rapid response.
Based on the current literature, the healing rates of
VLUs are comparable between ulcer MCS (ulcer kit)
and CB systems. This does not apply for circumferen-
tial ulcers or ulcers of larger size.
Recommendation 8: We recommend the use of ulcer MCS
(‘ulcer kits’) to improve VLU healing (GRADE 1A)
Recommendation 9: We recommend the use of ulcer
MCS (‘ulcer kits’) to reduce pain in patients with
VLU (GRADE 1A)
Prevention of clinical progression in chronic venous
disease. Prevention of CVD progression, such as from
lower clinical classes to more severe disease, including
VLU, is one of the main goals of treatment. There is
insuﬃcient information from RCTs on the prevention
of CVD progression by MCS that would allow for an
evidence-based recommendation. However, in a case–
control study by Kostas et al.,29 who investigated CVD
progression in the contralateral leg of patients treated
for varicose veins, non-compliance with compression
was reported as one of the risk factors for overall
CVD progression.
Recommendation 10: Insuﬃcient data are available on
the use of MCS for the prevention of CVD progression,
so we recommend further studies are needed to be able
to make evidence-based recommendations
Reduction of side effects after venous interventions. The use
of post-treatment compression to reduce side eﬀects
such as pain, oedema, bruising and thromboembolic
events is suggested in most guidelines, in regard to
venous interventions for varicose veins including high
ligation and stripping, endovenous thermal ablation or
sclerotherapy. The duration of compression therapy is
not clearly deﬁned in most of the guidelines and, over
the past decade, endovenous procedures have become
signiﬁcantly less invasive, as a result of the introduction
of new devices and methods.
Most RCTs have been limited to great saphenous
vein (GSV) interventions. One paper on compression
after interventions for subcutaneous varicose veins sug-
gests that less traumatizing surgical methods may not
need post-procedural MCS.30
Results from one RCT are available after sclerother-
apy in C1 varicose veins.31 Therefore, evidence-based
recommendations can only be given for C1 varicose
veins.
Older studies have compared diﬀerent types or dur-
ations of compression therapy without concluding
whether compression after interventions is beneﬁcial or
not, or on the optimal treatment duration.32–36
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In a more recent RCT, Houtermans-Auckel et al.37
reported that wearing MCS for four weeks after high
ligation and stripping of the GSV, following CB use for
three days, had no additional beneﬁt on limb oedema,
pain, complications and return to work. In a rando-
mised study comparing thromboembolic-deterrent
(TED) stockings for one or three weeks after GSV,
high ligation and stripping, and three days of post-
operative bandaging, Biswas et al.38 reported no beneﬁt
in wearing TED stockings for more than one week with
respect to postoperative pain, number of complications,
time to return to work and patient satisfaction for up to
12 weeks following surgery. Mariani et al.39 compared
MCS (23–32mmHg) with CB after varicose vein sur-
gery, and reported no diﬀerence in postoperative pain,
but improvement of oedema and QoL in the stocking
group after seven days. A study by Mosti et al.40
included 54 patients who had invagination stripping
of the GSV and side-branch evulsion under local anaes-
thesia and were treated for one week, postoperatively,
either by thigh-length compression stockings, adhesive
bandages or eccentric compression pads ﬁxed with
tapes and a superimposed thigh-length stocking on
top. Eﬀective reduction of pain and hematoma was
obtained with a high local pressure by eccentric com-
pression pads taped to the skin along the stripping
channel and a compression stocking on top. Benigni
et al.41 compared pain intensity on Days 1 and 7 and
global mean pain during the week following stripping
of the GSV in patients for whom either a pad had been
added at thigh level under an MCS or patients with an
MCS only. Pain was signiﬁcantly reduced in the pad
plus MCS group (p< 0.0001). Lugli et al.42 compared
postoperative pain for one week after endovenous laser
ablation of the GSV in patients using a special crossed-
tape technique that produces higher eccentric compres-
sion, compared with those not using pads. In the group
using the tape technique, postoperative pain was signiﬁ-
cantly reduced (p< 0.001).
Bakker et al.43 reported that MCS for periods longer
than two days after endovenous GSV ablation without
simultaneous phlebectomies reduce pain and improve
physical function during the ﬁrst week after treatment.
Reich-Schupke et al.44 reported that 23–32mmHgMCS
are superior to 18–21mmHg MCS, providing faster
resolution of clinical and ultrasound-veriﬁed oedema
and feelings of pain, tightness, and discomfort of the
leg in the ﬁrst week after varicose vein surgery, but not
in the longer post-surgical period up to six weeks.
Regarding pain or complications after foam sclerother-
apy of the GSV, Hamel-Desnos et al.45 found no signiﬁ-
cant diﬀerence between patients whowerewearing 15–20
mmHg thigh-highMCS and those without compression.
Kern et al.31 reported that wearing MCS (23–
32mmHg) for three weeks can enhance the eﬃcacy of
sclerotherapy of C1 varicose veins by improving clinical
vessel disappearance.
Most of the available studies have limitations. In
many cases, the interface pressure is not reported or
very low. The data, however, show no beneﬁt of
MCS for time periods of longer than a week.
Three studies have shown that local high interface
pressure, along the GSV at the thigh, can reduce
pain.40–42
In summary, one week of MCS treatment using
thigh-length 20–40mmHg stockings after GSV inter-
ventions can be recommended. Pressure enhancement
along the treated vein with additional eccentric padding
may be helpful.
Recommendation 11: We recommend the use of MCS
in the initial phase after GSV treatment to reduce post-
operative side eﬀects (Grade 1B)
Recommendation 12: We recommend additional eccen-
tric compression to enhance the eﬀectiveness of MCS in
the reduction of postoperative side eﬀects (Grade 1B)
Improvement of therapeutic outcome after venous
interventions. The clinical beneﬁt of ongoing MCS
treatment after successful correction of pathological
changes in the superﬁcial system, or after the reduc-
tion of recurrent varicose veins, warrants recommen-
dation of long-term MCS use in these scenarios. Older
studies have been unable to show a beneﬁt for inter-
mediate- or long-term use of MCS after venous inter-
ventions.32–36 A better cosmetic outcome after three
weeks of compression stocking was shown in only
one trial in which small spider veins had been trea-
ted.31 The more recent studies either did not follow
the patients for a long enough period of time or had
failed to demonstrate beneﬁts from ongoing MCS use
after the initial postoperative period.37–42,45 However,
not all patients return to asymptomatic clinical class
C0 after venous interventions, even if they have
improved clinically, and so may still require MCS
treatment. These patients include those who are
post-thrombotic after superﬁcial insuﬃciency treat-
ment, or patients with healed or active VLU, after
varicose vein treatment. Prevention of ulcer recurrence
still includes MCS use.
Recommendation 13: We do not recommend routine,
prolonged use of MCS for improving clinical success
after GSV interventions, except for those patients with
ongoing symptomatic CVD that beneﬁt from a contin-
ued MCS treatment (Grade 1B)
Recommendation 14: We suggest the use of MCS after
liquid sclerotherapy of C1 veins to achieve better out-
comes (Grade 2B)
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Patients with acute venous disorders
Deep vein thrombosis
Use of compression in combination with an eﬀective
anticoagulant to mobilise patients with acute DVT
has long been used in Europe, and is the basis for
modern home-based therapy.46 Home treatment
became accepted for the management of acute DVT
after reports that walking with compression does not
lead to a higher incidence of pulmonary embolism (PE),
compared with bedrest.47,48 There is, however, a pau-
city of evidence from RCTs on the beneﬁts of compres-
sion for acute DVT.
Reduction of pain
In a study in patients with proximal DVT, Bla¨ttler and
Partsch49 assessed the rate of clinical improvement with
compression plus immediate deliberate ambulation, in
comparison with bedrest without compression, using a
visual analogue scale (VAS) to monitor pain and
a modiﬁed Lowenberg test to monitor provoked pain.
The study demonstrated superiority of compression
(stockings or bandages), over bedrest without compres-
sion, for the reduction of pain.49 Roumen-Klappe
et al.50 evaluated the eﬀect of immediate bandaging
vs. no bandaging on the development of PTS. They
reported that improvement of clinical symptoms and
decrease of leg circumference was signiﬁcantly better
on Day 7 after compression, compared with no
compression.
However, it has been reported that when compres-
sion is initiated after two weeks or more, there is no
diﬀerence between compression- and placebo-stockings
in the resultant pain levels.51
Reduction of oedema
Swelling of the aﬀected leg – a sign that is easily quan-
tiﬁable in acute proximal DVT – is rarely reported in
studies.
Bla¨ttler and Partsch49 measured diﬀerences in max-
imal calf circumference in patients with unilateral,
acute proximal DVT and reported that, in the ﬁrst
nine days, oedema was signiﬁcantly reduced with com-
pression, compared with bedrest and no compression
(p< 0.001).
Improvement of walking and QoL
Walking ability, as assessed by quantifying the daily
walking distance, was investigated only in one
study.49 Compression from bandages and stockings
was able to increase the mean daily walking distance
from 2km (at Day 1), to 4 km (at Day 9). A signiﬁcant
improvement in QoL parameters – particularly those
related to physical functioning – was demonstrated in
the group using compression, compared with those
using bedrest and no compression (p< 0.05 for stock-
ings; p< 0.001 for bandages).49
Recommendation 15: We recommend immediate com-
pression to reduce pain and swelling, thereby allowing
instant mobilisation in acute DVT (Grade 1B)
Reduction of thrombus growth
Arpaia et al.52 randomly assigned 73 patients with DVT
to elastic compression hosiery starting either immedi-
ately after diagnosis or two weeks afterwards. The resi-
dual thrombus was measured by compression
ultrasonography after 14 and 90 days. The investigators
reported that, in the group treated with early compres-
sion, there were signiﬁcantly more recanalised venous
segments than in the group treated with delayed com-
pression. Additionally, recanalisation of popliteal DVT
veins, expressed as the reduction of vein diameter, was
better in the early compression group than in controls
at both Day 14 and 90. Bla¨ttler and Partsch49 reported
less thrombus progression with compression, compared
with no compression, as assessed by ultrasound.
Recommendation 16: We recommend immediate com-
pression and mobilisation in addition to anticoagula-
tion to avoid thrombus propagation in acute DVT
(Grade 1B)
Superficial vein thrombosis
A Cochrane review of RCTs evaluating topical, medical
and surgical treatments for superﬁcial thrombophlebitis
included several RCTs that, over the past few years,
have reported beneﬁcial eﬀects of diﬀerent anticoagula-
tion regimens with compression stockings as an adjunct
treatment modality in superﬁcial vein thrombosis
(SVT).53 Boehler et al.54 compared the eﬀect of thigh-
length compression stockings (21–32mmHg) versus no
compression for a period of three weeks, to understand
the therapeutic eﬀect on isolated SVT of the legs. All
patients received low-molecular-weight heparin
(LMWH), and non-steroidal anti-inﬂammatory drugs
(NSAIDs) were allowed. The primary outcome variable
was the reduction of pain, as assessed by a VAS and the
Lowenberg test. Secondary outcomes were the con-
sumption of analgesics, thrombus length, skin ery-
thema, D-dimer, and QoL. There was no signiﬁcant
diﬀerence between the groups for all tested outcome
variables. At Day 7, patients in the compression
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stocking group had experienced a signiﬁcantly faster
thrombus regression (p¼ 0.02). The outcome
of this study does not exclude potential beneﬁts of
stronger compression bandages, worn day and
night. Experience from routine practice, as high-
lighted in the 2012 SVT consensus statement,
has emphasized that compression of the thrombosed
vein relieves the symptoms of SVT and accelerates
healing.55
Recommendation 17: We recommend MCS in patients
with SVT (Grade 1C).
In patients with SVT who are treated with LMWH,
aside from a reduction of thrombus growth after 1
week, an additional beneﬁt for symptomatic outcomes
has not been demonstrated
Post-thrombotic syndrome
Post-thrombotic syndrome (PTS) is a common compli-
cation of DVT caused by chronic damage to the venous
outﬂow.56 Besides the mechanical ﬂow disturbances
due to ﬂow obstruction and reﬂux, a chronic inﬂamma-
tory process with ongoing remodelling of the venous
wall is also responsible for clinical symptoms, and
these have been featured in the scoring system proposed
by Villalta and Prandoni.57 This score records the pres-
ence and severity of ﬁve symptoms (cramping, heavi-
ness, pain, paraesthesia, pruritus) and six clinical signs
(calf tenderness, induration, oedema, pigmentation,
redness, venous ectasia) with the inclusion of venous
ulceration as the most severe stage.3
The additional use of the CEAP system has been
recommended to provide further information.58
Importantly, clinical changes should also be described
in the acute phase of DVT.
Two RCTs have separately reported the beneﬁts of
wearing elastic compression stockings (ECS), in terms
of the risk of PTS.59,60 In a subsequent study, Prandoni
et al.61 stated that thigh-high compression stockings
were no more eﬀective than knee-high stockings, but
were less well tolerated. Aschwanden et al.62 conducted
an RCT whereby patients were assessed six months
after routine compression with MCS; it was reported
that prolonged compression therapy after proximal
DVT signiﬁcantly reduces the symptoms associated
with PTS, and may prevent post-thrombotic skin
changes. Musani et al.63 concluded, from a meta-
analysis of ﬁve RCTs, that wearing MCS after DVT
reduces the incidence of a PTS.
The ﬁndings of these studies have been challenged by
Kahn et al. in a large multicentre RCT that did not ﬁnd
signiﬁcant diﬀerences in the cumulative incidence of PTS
deﬁned with Villalta’s scale between patients who were
randomized to 30–40mmHg stockings or to placebo
stockings.64 This study has, however, been criticised by
a number of groups. Poor compliance, diﬀerences in
patients’ characteristics, the use of diﬀerent anticoagu-
lants (including new oral anticoagulants), the use of ‘pla-
cebo-stockings’ which may have been eﬀective and the
delay in the application of MCS have been suggested as
possible explanations for the lack of eﬀectiveness of ECS
in this trial.65,66 However, it must be highlighted that the
studies supporting compression to prevent PTS also have
limitations (e.g. lower number of included patients). In a
recent RCT,67 in which both the Villalta-Prandoni Score
and Venous Clinical Severity Score instruments were
used to monitor PTS, the MCS group had a lower inci-
dence of PTS, comparedwith the control group, but only
at the one-month cut-oﬀ. At 6 or 12 months, no diﬀer-
ence in the incidence of PTS was detected between the
groups. This result highlights the importance of the
immediate application of MCS in the acute phase of
DVT.67
A meta-analysis of eight RCTs concluded that the
evidence to date supports the use of compression for
reducing the risk of PTS. Nevertheless, the authors
stated that the ﬁndings need to be interpreted with cau-
tion, in view of the heterogeneity in the studies that
were included in the meta-analysis.68 Individualising
management for patients is undergoing investigation
and is expected to provide further insight into how to
provide patients with optimal management choices.69
The consensus panel concluded that current evidence
still supports compression therapy for PTS prophylaxis
in clinical practice, at least in symptomatic patients.
Recommendation 18: We recommend the use of MCS
as early as possible after diagnosis of DVT in order to
prevent PTS (Grade 1B)
Comment: Current evidence still supports compression
therapy for PTS prophylaxis in clinical practice, at least
in symptomatic patients
Therapy of PTS
Data on the physical management of PTS are
sparse;66,70,71 the most valuable data are obtainable
fromulcer-healing studies, because VLUs are considered
the severest form of post-thrombotic syndrome and PTS
are the main cause of the ulceration in many cases. A
systematic literature review conducted to identify the
most superior compression method for promoting ulcer
healing and reducing recurrence in patients with lower
extremity venous ulcer disease determined that moder-
ate-quality evidence supports the use of compression and
low-quality evidence supports the eﬀect of compression
on ulcer recurrence.72
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Recently, Lattimer et al.73 have reported on the
beneﬁts of compression on haemodynamic parameters
in PTS.
Recommendation 19: We recommend the use of MCS
for the treatment of symptomatic PTS (Grade 1B)
Thromboprophylaxis
Two types of compression garments are used for
thromboprophylaxis: thromboprophylactic stockings
(TPS) and MCS. TPS with a pressure range between
15 and 18mmHg should be diﬀerentiated from MCS
that are speciﬁcally designed for patients with venous
or lymphatic pathology. TPS are able to decrease the
venous diameter in the prone position, thereby increas-
ing venous blood ﬂow velocity, which provides the
physical conditions needed to avert blood ﬂow stagna-
tion.74 TPS are therefore indicated during bedrest,
though not for fully mobilised patients.
MCS that are speciﬁcally designed for patients with
a venous or lymphatic pathology are also preferred for
use in individuals when in sitting positions (e.g. using a
wheelchair, during long-distance travel).
Avoid DVT after surgical interventions
In an era of increasingly well-tolerated and eﬀective
anti-thrombotic drugs, the role of TPS has become
less prominent, although there is a large body of evi-
dence in support of their eﬀectiveness.
Early pioneering work by Turpie et al.,75 using
radiolabelled ﬁbrinogen scanning, has demonstrated
that TPS alone or in combination with IPC is eﬀective
in preventing DVT in neurosurgical patients.
Several RCTs have demonstrated a signiﬁcant reduc-
tion in thromboembolic events in neurosurgical patients
when stockings were used in combination with anti-
coagulants, compared with stockings alone.76,77 A
Cochrane review that compared TPS alone vs. TPS
with other DVT prophylactic methods, based on 19
RCTs, concluded that TPS reduced the incidence of
DVT after surgery.78 However, the scientiﬁc evidence
is questionable, in view of the dubious combination of
physical and pharmacological prophylaxis used.78 In
patients for whom anticoagulants are contraindicated,
physical modalities – including TPS, as well as IPC – are
still recommended.79–81
An international consensus report recommends the
use of TPS in addition to early ambulation and suﬃ-
cient hydration, for patients undergoing minor surgery
with low risk (low level of evidence). Anticoagulant
prophylaxis is recommended for moderate- and high-
risk patients undergoing surgery.82
In high-risk patients undergoing abdominal surgery,
a combination of TPS and IPC is more eﬀective than
TPS alone.83
Well-ﬁtting stockings are recommended in patients
with VLUs or venous leg oedema during and after sur-
gery, independent from thromboprophylaxis.82
The question of whether use of TPS oﬀers a further
signiﬁcant beneﬁt as an adjunct to pharmacological
thromboprophylaxis in surgical inpatients was investi-
gated in a recent systematic review of 27 RCTs. No
clear beneﬁt of adding TPS to pharmacological throm-
boprophylaxis in such patients could be identiﬁed,
mainly because of the heterogeneity of the results,
which precluded a valid summation analysis.84
For patients undergoing orthopaedic surgery, the
addition of TPS use to an eﬀective anticoagulant has
been questioned.85–87
Chin et al.87 reported that the use of TPS alone is
able to reduce DVT in Asian patients who have had a
total knee replacement, in comparison to a control
group of patients, although IPC and enoxaparin were
found to be more eﬀective.
Recommendation 20: We suggest the use of thrombo-
prophylactic stockings as a basic component of mech-
anical prophylaxis in patients undergoing major
surgery (Grade 2C)
Recommendation 21: Mechanical methods of throm-
boprophylaxis, including thromboprophylactic stock-
ings, should be considered, especially where
anticoagulants are contraindicated (Grade 2B)
DVT prophylaxis in medical patients and
long-distance travellers
In recent years, there has been an increase in research
on venous thromboembolism (VTE) prevention in
high-risk scenarios, particularly in hospitalised medical
patients, outpatients with cancer, chronically immobi-
lised patients, long-distance travellers, and in patients
with asymptomatic thrombophilia.
Scurr et al.88 described asymptomatic calf vein
thrombosis after long-haul ﬂights in 10% of passen-
gers without compression stockings, while those who
wore MCS did not develop DVT. Clarke et al.89 con-
ducted a Cochrane review to assess the eﬀectiveness of
MCS for preventing DVT in long-haul travellers and
concluded that airline passengers can expect a sub-
stantial reduction in the incidence of symptomless
DVT and leg oedema if they wear compression
stockings.
Several consensus meetings have proposed the
use of LMWH and/or MCS in high-risk long-distance
travellers.90
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Mechanical thromboprophylaxis with MCS or IPC
was recommended by Kahn et al.79 for acutely ill hos-
pitalised patients at increased risk of thrombosis who
are bleeding or are at high risk of major bleeding, at
least until the bleeding risk is decreased.
Recommendation 22: We suggest the use of MCS
during long-distance travelling, to prevent DVT inci-
dence in patients at risk (Grade 2B); in high-risk
patients, we suggest a combination of MCS with anti-
coagulant thromboprophylaxis (Grade 2C)
DVT prophylaxis in stroke patients
There is a paucity of information on the prevention of
VTE among high-risk patients.91 The CLOTS trials,
which investigated patients who have had a stroke, pro-
vide reliable data. In the outcome-blinded RCT of 2518
patients (CLOTS I), where the primary outcome was
the occurrence of symptomatic or asymptomatic DVT
in the popliteal or femoral veins, thigh-length TPS
caused skin problems in 5% of patients and did not
reduce the incidence of DVT.92 A comparison between
thigh-length and knee-length stockings (CLOTS II)
revealed that proximal DVT occurred more often in
patients with stroke who wore below-knee stockings
than in those who wore thigh-length stockings.93
A Cochrane review, conducted to determine whether
thigh-high or knee-high TPS would be more eﬀective in
postoperative surgical patients, reported that there is
insuﬃcient high-quality evidence to answer this
question.94
The CLOTS III trial demonstrated that IPC is an
eﬀective method of reducing the risk of DVT and pos-
sibly improving survival in a wide variety of patients
who are immobile after stroke.95
It may be assumed that TPS may help reduce depend-
ent oedema in stroke patients with reduced mobility.
Recommendation 23: We do not recommend below-
knee TPS as the sole method for DVT prophylaxis in
stroke patients (Grade 2B)
Recommendation 24: If TPS is considered in stroke
patients for DVT prophylaxis, we suggest the use of
thigh-length TPS over knee-length TPS stockings
(Grade 1B)
Patients with lymphoedema
Prevention of lymphoedema
There is paucity of data on the use of MCS for the
prevention of lymphoedema. A recent RCT that
compared thigh-length 21–32mmHg stockings with
usual care, 6 months after inguinal lymph node resec-
tion as a result of cancer, reported no signiﬁcant diﬀer-
ences between groups in the incidence of oedema,
median time to the occurrence of oedema, incidence
of genital oedema, frequency of complications, health-
related QoL (HRQoL), or body image.96
Comment: More trials are needed to clarify the poten-
tial role of compression stockings for preventing lym-
phoedema after surgery
Improvement of lymphoedema
Compression is certainly the most important compo-
nent in the context of ‘decongestive lymphatic ther-
apy’ (DLT) – both for the treatment and for the
maintenance phase. However, data endorsing this
concept are lacking.97 Appropriately ﬁtting compres-
sion garments are recommended for long-term
maintenance therapy.
A major problem in assessing the eﬃcacy of com-
pression garments in lymphoedema is that the use of
stockings in all studies was combined with additional
treatment modalities, and primarily manual lymph
drainage (MLD). In an RCT in which 95 patients
with breast cancer-related arm lymphoedema were ran-
domly assigned to either compression garments (con-
trol) or daily manual lymphatic drainage and
bandaging followed by compression garments (experi-
mental), Dayes et al.98 were unable to demonstrate a
signiﬁcant diﬀerence in improvement in lymphoedema
between the two groups. The authors indicated that the
failure to detect a diﬀerence may have been a result of
the relatively small size of the trial.
Johannsson et al.99 surveyed the current evidence, in
regard to the treatment of lymphoedema, and con-
cluded that less emphasis should be placed on MLD
and more on early diagnosis, compression, weight con-
trol and exercise, when managing patients with cancer-
related lymphoedema.
The published data are mainly on volume changes,
while symptoms and QoL assessments are inconsist-
ently reported. The traditional concept of starting lym-
phoedema therapy by compression bandages (‘therapy
phase’) followed by stockings (‘maintenance phase’) is
supported by the outcome of an RCT which demon-
strated that multilayer bandaging as an initial phase of
treatment for lymphoedema patients, followed by hosi-
ery, achieves greater and more sustained limb-volume
reduction than hosiery alone.100
MCS are mainly used to maintain long-term lym-
phoedema reduction. There is evidence that high-
compression stockings (30–40mmHg) are eﬀective;
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generally, the highest level of compression that the
patient can tolerate (20–60mmHg) is likely to be the
most beneﬁcial.101
Recommendation 25: We recommend the use of MCS
for lymphoedema maintenance therapy (Grade 1A)
Discussion
The place of MCS in managing chronic and acute
venous and lymphatic disorders is discussed below.
Consideration of the eﬀectiveness of diﬀerent lengths
(below-knee, thigh-length, waist-high, etc.), compres-
sion pressures, or degrees of stiﬀness of MCS has not
been included because information about the inﬂuence
of these factors on therapeutic outcomes is either miss-
ing or associated recommendations have been
inconsistent.
Importantly, we acknowledge that several studies
have limitations that led to lower grading of a
number of the recommendations. Limitations include
low numbers of patients included in the respective stu-
dies, as well as instances where MCS was not compared
with no compression or placebo. In some studies, the
comparator MCS had diﬀerent pressure levels or a dif-
ferent compression method was applied; thus, a fair
comparison of the interventions was not done.
Chronic venous disorders
In chronic venous disease, MCS are now a main indi-
cation for the improvement of venous symptoms, QoL
and oedema (Grade 1B). This is particularly true for the
treatment of occupational leg oedema and the reduc-
tion of venous symptoms/oedema during long-distance
travel (Grade 1B).
The clinical observation that stockings reduce the
pigmentation and induration of lipodermatosclerosis
and venous eczema has not been conﬁrmed in large
clinical trials, because of the methodological diﬃculties
of measurement. More studies are needed to conﬁrm
their beneﬁt in treating venous skin changes.
The use of MCS on ulcer recurrence prevention is
well documented (Grade 1A). However, evidence on
their use in treating established ulcers is less clear.
Since the 2008 consensus document,4 specially designed
ulcer MCS (ulcer kits) have been developed. They con-
sist of a two-layer stocking system for uniform gradu-
ated compression and ease of application. Their
beneﬁcial eﬀect on VLU healing has been reported in
several clinical trials.26,28
Although it is intuitive that MCS reduce the relent-
less radial tension in veins during dependency, there is
still insuﬃcient information available to recommend
their use for the prevention of CVD progression.
Further studies are required for an evidence-based
recommendation.
As recommended in most of the current recommen-
dations and guidelines, compression has become stand-
ard practice after varicose vein surgery to reduce
bruising, pigmentation, pain and oedema, and also to
improve eﬃcacy.102 Now that venous interventions
have become minimally invasive, fewer side eﬀects
may be expected. Consequently, the need for compres-
sion is less clear. Recent studies indicate that in most of
the interventions there is still a beneﬁt of MCS during
the ﬁrst post-interventional week.38,39,44 These ﬁndings
relate especially to the reduction of pain, oedema and
bruising.
Information on the long-term beneﬁts derived from
the use of MCS in the early postoperative phase is lack-
ing in the literature. Interestingly, some beneﬁt after
sclerotherapy in C1 varicose veins has been reported.
31
In patients with ongoing CVD symptoms, despite
previous interventions, a continuation of compression
therapy with MCS is still indicated. Unfortunately, stu-
dies that compare MCS with no compression or placebo
compression are rare. More commonly, diﬀerent types
of compression have been compared, but with inconsist-
ent results falling short of any recommendation.
Acute venous disorders
The recommendation to use MCS in the acute stage of
DVT to reduce pain and swelling and allow immediate
ambulation is based on two studies.49,50 Although this
regime has been widely accepted,103,104 more studies are
needed on optimal compression therapy. Research
questions that still need to be addressed include:
should the length of the stocking be adjusted to the
level and extent of the disease?; what compression
strength is best, and for how long?; and should the
mobility of the patient be taken into consideration?
Ideally, such studies should begin in the acute stage,
after conﬁrmation of the diagnosis, and should concen-
trate not only on the morphology of the thrombus, but
also on the reduction of leg swelling, pain, and on
improving QoL. Similar considerations should be
applied to the use of MCS in SVT. However, to date,
only one such RCT has been conducted.54 Well-
conducted studies will be able to determine the extent
and beneﬁt of MCS in the long-term prevention of PTS.
Implantable electronic devices sewn into the fabric of
the stocking should help improve treatment because
they have the potential to provide feedback on usage.
This approach may be necessary to record patient com-
pliance, because this remains one of the major chal-
lenges in the management of venous or lymphatic
disorders.
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An alternative approach is to provide some type of
awareness training to remind the patient regularly
about the usefulness of compression therapy.
However, though rewarding, such training is very
time consuming. The immediate feeling of relief from
pain and swelling in the acute stage of venous throm-
bosis, combined with the assumption that MCS reduce
further thromboembolic events, may be the best argu-
ment to maximise patient compliance.
Insuﬃcient data are available from prospective
RCTs for identifying those patients requiring treatment
with MCS, for the purpose of preventing PTS.
Whilst those patients with proximal DVT and a high
thrombus burden seem to be the most suitable for treat-
ment, PTS is frequently seen in patients without a clear
diagnosis of previous DVT. This suggests that all
patients may beneﬁt from MCS after DVT. In agree-
ment with recommendations 3–5 in this document, a
high-level recommendation for using MCS in such
patients can be justiﬁed (Grade 1B).
TPS were recommended for bedridden patients in the
2008 consensus (Grade 1A).4 However, their value has
been questioned in the light of recent trials.78,92,93 This is
because prescription of the newer and very eﬀective anti-
thrombotic drugs make it diﬃcult to attribute a poten-
tially positive treatment eﬀect to the use of TPS.
This document recommends the use of TPS as a
component of mechanical prophylaxis in patients
undergoing major surgery (Grade 2C). Correctly mea-
sured TPS should be considered in all patients where
anticoagulation is contraindicated (Grade 2B).
Stocking–skin interface pressures can be measured
easily with small portable devices. They are recom-
mended clinically to ensure a good compression proﬁle,
especially for legs of non-standard proportions, and are
recommended in all research studies.
Lymphatic disorders
The beneﬁcial eﬀect of MCS in the maintenance of
long-term lymphoedema reduction is undisputed and
well documented (Grade 1A). However, detailed stu-
dies are required to examine their potential role for
the prevention of lymphoedema after radiotherapy,
cancer and lymph-node dissection. In selecting outcome
parameters for such studies, there should be consider-
ation not only of the oedema, but also of the mobility
of the patients, their QoL and the ease of applicability
of compression garments.
Other indications
Compression has an anti-inﬂammatory eﬀect and is
often recommended for inﬂammatory conditions that
have an oedema component. These may include
cellulitis, some forms of vasculitis, and systemic medical
treatments. Compression stockings may help also in the
reduction of oedema and nausea during pregnancy.
There is a growing demand for their use in sports medi-
cine where they may have an eﬀect on reducing recov-
ery time. In these cases, compression can be used with
good clinical success in daily practice but there is a lack
of randomised comparative studies that have examined
these indications.105
Contraindications
It is best practice not to oﬀer MCS to patients with
severe congestive cardiac failure, as there is a risk that
they may develop systemic ﬂuid overload. However,
reducing moderate oedemas, without shifting larger
blood volumes towards the right heart, can be achieved
using light MCS.
Another successful indication for light MCS
could be the post-reconstructive oedema after success-
ful bypass surgery. The use of light MCS
(15–21mmHg) in these two indications is based on clin-
ical experience only, and deserves further study in the
future.
In patients with critical limb ischaemia, with systolic
ankle pressure below 70mmHg or following arterial
bypass grafting, compression stockings are contraindi-
cated as there is a risk of ischaemia or local skin necro-
sis, especially if the limb is elevated.
There are other local conditions in which stockings
may cause damage. These include advanced peripheral
neuropathy, fragile tissue paper skin over the bony
prominences, dermatitis and allergic reactions to the
fabric.
For unusual leg sizes, shapes or deformities, a stand-
ard ‘oﬀ-the-shelf’ stocking is unlikely to ﬁt the patient.
In these cases, MCS should be customised to the indi-
vidual limb measurements.
Conclusion
This consensus document reports an update of the
scientiﬁc evidence on the use of MCS in venous
and lymphatic disorders. Compared with the ICC
consensus document in 2008, several new RCTs
have been published showing the improvements that
MCS provide in reducing venous symptoms and
signs. Although more research is always required,
the place of MCS as a treatment is now ﬁrmly estab-
lished for most venous and lymphatic conditions, as
well as for venous symptoms in healthy people. The
consensus statement was awarded ﬁrst prize in the
oral abstract presentation section at the 30th
Annual Congress of the American College of
Phlebology 2016, Anaheim, California.
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